Related Experiment Video
Updated: Jun 5, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Statins for secondary prevention of cardiovascular disease: the right dose
Reynold Spector1, Steven M Snapinn
1Robert Wood Johnson Medical School, Piscataway, NJ, USA. mspec007@verizon.net
Insights
For coronary artery disease patients, high-dose statins offer no mortality benefit and increase adverse events. A single, safe 40 mg dose of simvastatin or atorvastatin is recommended for cost-effectiveness and improved medication compliance.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Statins are widely accepted for reducing cardiovascular events in coronary artery disease (CAD).
- Controversy exists regarding optimal statin dosage and the necessity of cholesterol-lowering goals.
Purpose of the Study:
- To determine the optimal statin dose in CAD patients by analyzing dose-response data.
- To evaluate the mortality benefit, efficacy, and safety of higher statin doses.
Main Methods:
- Meta-analysis of three large, long-term (approx. 5 years) dose-clinical response studies (TNT, IDEAL, SEARCH).
- Comparison with historical data, including long-term safety information.
Main Results:
- Increasing simvastatin or atorvastatin to 80 mg provided no mortality advantage over lower doses.
- Higher doses showed only a marginal reduction in myocardial infarctions and strokes, with increased adverse reactions.
- A single 40 mg dose of generic simvastatin or atorvastatin is suggested as a cost-effective, safe option.
Conclusions:
- High-dose statins (80 mg) are not superior to lower doses for mortality benefit in CAD patients.
- A 40 mg dose of inexpensive statins is sufficient and cost-effective for most CAD patients.
- Treatment-to-goal strategies and routine cholesterol monitoring may be unnecessary, potentially improving medication adherence.
Abstract:
Since the publication of the 4S trial in 1994, there has emerged a consensus that statins save lives and decrease myocardial infarctions and strokes in coronary artery disease (CAD) patients irrespective of baseline serum cholesterol. However, there is controversy over the correct dose and the utility of the treatment-to-goal (cholesterol, low-density lipoprotein) approach. To answer remaining questions about the optimal statin dose in CAD patients, we have performed simple and meta-analyses of 3 large long-term (approx. 5 years) dose-clinical response studies (TNT, IDEAL, and SEARCH) and compared the results with older data including long-term safety data. The results show that raising the dose of simvastatin or atorvastatin to 80 mg confers no mortality advantage, an increase in adverse reactions and only a slight decrease in myocardial infarctions and stroke versus a lower dose. These results suggest a cost-effective approach of a single safe dose (40 mg of inexpensive generic simvastatin or atorvastatin) for almost all CAD patients and makes treatment-to-goal and cholesterol monitoring (except to check for medication compliance) unnecessary; moreover, it is likely to improve the weakness in statin use - medication compliance.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Coronary Artery Disease IV: Preventive Measures
Rational Dosage Regimen: Maintenance Dose and Loading Dose
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady state,...
Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Coronary Artery Disease V: Interprofessional Care